Edition:
United States

Abbott Laboratories (ABT)

ABT on New York Consolidated

43.67USD
27 Jul 2016
Change (% chg)

-- (--)
Prev Close
$43.67
Open
--
Day's High
--
Day's Low
--
Volume
200
Avg. Vol
9,780,272
52-wk High
$51.24
52-wk Low
$36.00

ABT

Chart for ABT

About

Abbott Laboratories (Abbott) is engaged in the discovery, development, manufacture and sale of a line of healthcare products. The Company operates in four business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment... (more)

Overall

Beta: 1.03
Market Cap(Mil.): $64,157.87
Shares Outstanding(Mil.): 1,469.15
Dividend: 0.26
Yield (%): 2.38

Financials

  ABT Industry Sector
P/E (TTM): 33.52 36.73 37.52
EPS (TTM): 1.30 -- --
ROI: -- 15.28 14.48
ROE: -- 16.33 15.65

US STOCKS-Microsoft helps Wall St to another day of record highs

* Indexes up: Dow 0.19 pct, S&P 0.43 pct, Nasdaq 1.06 pct (Updates with close of U.S. market)

Jul 20 2016

US STOCKS-Microsoft propels Wall Street to new record highs

* Indexes up: Dow 0.24 pct, S&P 0.47 pct, Nasdaq 1.13 pct (Updates to late afternoon)

Jul 20 2016

Abbott sales beat on higher demand for medical devices

Abbott Laboratories reported better-than-expected quarterly sales and profit as strong sales in its medical device business more than made up for the hit from an economic turmoil in Venezuela.

Jul 20 2016

UPDATE 3-Abbott sales beat on higher demand for medical devices

* Shares up 2.3 pct (Adds details about St. Jude, Alere acquisitions and share move)

Jul 20 2016

BRIEF-Abbott reports Q2 2016 GAAP earnings per share $0.40 from continuing operations

* Q2 total diagnostics sales $1,226 million versus $1,177 million last year

Jul 20 2016

Abbott Labs reports 3.2 percent rise in sales

July 20 Abbott Laboratories reported a 3.2 percent rise in quarterly sales, helped by strength in its branded generics and medical device businesses.

Jul 20 2016

BRIEF-Health Canada approves Abbott's 'Absorb' bioresorbable stent

* Health Canada approves Abbott's Absorb bioresorbable stent, the first fully dissolving heart stent

Jul 14 2016

BRIEF-St Jude and Abbott Labs receive request for additional information from U.S. FTC

* Abbott labs, st. Jude medical each received request for additional information from u.s. Ftc relating to abbott's potential acquisition of st. Jude medical

Jul 12 2016

BRIEF-SA's Competition Commission says to probe Transnet for excessive pricing

* Initiated an investigation against Transnet SOC Ltd for excessive pricing and exclusionary practices

Jul 07 2016

Abbott wins U.S. approval for stent that absorbs into body

U.S. health regulators said on Tuesday they approved a stent by Abbott Laboratories that is the first designed to be absorbed into the bloodstream after it is implanted.

Jul 05 2016

Competitors

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Stock Traders Daily
$20.00
Provider : New Constructs, LLC
$25.00
Provider : Thomson Reuters Stock Report
$25.00
Provider : Wright Reports
$75.00
Provider : MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.